Royalty Report: Diagnostic, Drugs, Imaging – Collection: 146988


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 4


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4

Primary Industries

  • Diagnostic
  • Drugs
  • Imaging
  • Device
  • Medical
  • Cancer
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 146988

License Grant
Previously the parties entered into an International License Agreement, whereby Licensee obtained certain exclusive marketing rights for certain territories outside of the United States, subject to limited Licensor co-promotion rights, to certain ultrasound contrast agents.

As of the Amendment Effective Date, Licensor has under development an imaging product and Licensee has the exclusive rights to market and sell the imaging product.

License Property
The licensed property is an ultrasound diagnostic imaging product.
Field of Use
This imaging is used for Cardiology, Radiology and perfusion Indications.

IPSCIO Record ID: 383590

License Grant
By this agreement, the Parties intend to enter into a restructured relationship.

For Patent License to Licensee of Germany, Licensor grants an exclusive license under the Licensor Patents and the Licensor Know-How to develop, market, sell, and distribute the Product in the Licensee Territory. Such license with respect to the TV Indication shall terminate on the Option 1 Effective Date, and, with respect to all of the countries of the world for all indications, excluding however the TV Indication, shall terminate on the Option 2 Effective Date.

For the Licensor HI Patents, Licensor grants a non-exclusive worldwide license, without a right to sublicense to any other party than Affiliates, under the Licensor HI Patents to use, develop, manufacture, have manufactured, market, sell and distribute product for use as an ultrasound contrast agent.

License Property
Licensor has certain technology for use in ultrasound imaging techniques.

AF0150 means a white powder which, after reconstitution with appropriate diluent, forms an aqueous suspension of perfluorohexane/nitrogen-filled microbubbles with the formulation employed in Phase II Clinical Trials under the United States IND 49,978.

CAD Indication means the indication of an ultrasound agent for the intravenous administration during two-dimensional gray-scale echocardiography examination including stress echocardiography for the differentiation of infarcted from ischaemic areas of the myocardium.

LV Indication means the indication of an ultrasound agent for manual intravenous administration during two-dimensional gray-scale echocardiography examination for improved assessment of global left ventricular function ( e.g. border delineation, ejection fraction, wall motion) at rest and during stress.

Product means AF0150 and any drug compounds, drug compositions and medical devices and systems related to perfluorocarbon containing ultrasound imaging products and developed by Alliance pursuant to this Agreement, and, with Licensee pursuant to the Original License Agreement, which, in the absence of this Agreement, the use, development, manufacture, marketing, sale or distribution of which would result in the infringement of one or more claims in an Alliance Patent or which utilize the Alliance Know-How. For ease of reference, Product is generally expressed in the singular in this Agreement, but multiple Products may be Developed or marketed hereunder.

Field of Use
The Field means, at any date of determination, the development, use, manufacture, distribution, marketing and sale of the Product as an ultrasound contrast agent in all possible indications, in humans or animals.

IPSCIO Record ID: 1548

License Grant
The Licensor granted Licensees of Norway exclusive developmental, manufacturing, and marketing rights for Albunex-Registered Trademark-and other gas-filled albumin microsphere ultrasound imaging agents in the territory.  In October 1995 the parties entered into an amendment of their agreement that effectively returned these rights to the Licensor.
License Property
Albunex is a proprietary ultrasound contrast agent which consists of air-filled albumin microspheres, is used during echocardiography which is an ultrasound imaging of the heart to enhance the identification of endocardial borders and to assess blood flow within the cardiac chambers.
Field of Use
The rights granted apply to the medical industry.

IPSCIO Record ID: 237237

License Grant
Licensor, an individual, grants a nonexclusive, license, without the right to sublicense, under the Patent to make, have made, use, offer to Sell, Sell, import, export and otherwise transfer the MR Contrast Agent Product during the term of this Agreement.

With this Agreement, Licensor discharges, releases, promises and covenants not to sue, threaten to sue or otherwise disturb Licensee, and its Affiliates, and any Licensees Licensee, subcontractor, supplier, distributor, vendor, reseller, purchaser, or user of the MR Contrast Agent Product, acquired directly or indirectly from Licensee {or its Affiliates) or a Licensees Licensee in any country in the world, for any claim or cause of action based upon the Licensor MR Intellectual Property and the manufacture, use, Sale, advertisement, offer for Sale, importation, lease, or otherwise transfer or disposition of the MR Contrast Agent Product, whether such claim or cause of action is presently known or unknown.

License Property
MR ContrastAgent(s) means any contrast agent used in, or capable of use in CEMRA procedures.  CE-MRA means contrast-enhanced MR angiography.  MR means magnetic resonance imaging and magnetic resonance angiography.

Licensor is recognized for his expertise in clinical magnetic resonance imaging and magnetic resonance angiography and as the inventor of contrast-enhanced magnetic resonance angiography techniques.

MR Imaging System{s) means any magnetic resonance transmission/receiving system, inclusive of all hardware (for example, without limitation, imaging coils) and software components, that is capable of performing CE-MRA procedures.

IP relates to the magnetic resonance imaging drug, MS-325.

MS-325 is designed to provide visual imaging of the vascular system, through a type of MRI known as magnetic resonance angiography, or MRA.

Field of Use
The use of this agreement is to develop and commercialize contrast agents used in magnetic resonance imaging and magnetic resonance angiography.

MS-325 is specifically designed to enhance the quality of magnetic resonance images of the arteries and veins and to provide physicians with a superior method for diagnosing vascular disease.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.